Oppenheimer analyst Kevin raised his price target on Vericel (VCEL) to $32 from $23 after the company reported Q1 results, raised its 2019 revenue guidance and announced a deal to license North American rights for NexoBrid from MediWound (WDWD). He keeps an Outperform rating on Vericel shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.